Liposomal chemotherapeutics

Emanuela Gentile; Felisa Cilurzo; Luisa Di Marzio; Maria Carafa; Cinzia Anna Ventura; Joy Wolfram; Donatella Paolino; Christian Celia

doi:10.2217/FON.13.146

Liposomal chemotherapeutics

Emanuela Gentile, Felisa Cilurzo, Luisa Di Marzio, Maria Carafa, Cinzia Anna Ventura, Joy Wolfram, Donatella Paolino, Christian Celia

Biochemistry and Molecular Biology

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

Currently, six liposomal chemotherapeutics have received clinical approval and many more are in clinical trials or undergoing preclinical evaluation. Liposomes exhibit low toxicity and improve the biopharmaceutical features and therapeutic index of drugs, thereby increasing efficacy and reducing side effects. In this review we discuss the advantages of using liposomes for the delivery of chemotherapeutics, Gemcitabine and paclitaxel have been chosen as examples to illustrate how the performance of a metabolically unstable or poorly water-soluble drug can be greatly improved by liposomal incorporation. We look at the beneficial effects of liposomes in a variety of solid and blood-borne tumors, including thyroid cancer, pancreatic cancer, breast cancer and multiple myeloma.

Original language	English (US)
Pages (from-to)	1849-1859
Number of pages	11
Journal	Future Oncology
Volume	9
Issue number	12
DOIs	https://doi.org/10.2217/FON.13.146
State	Published - 2013

Keywords

Cancer therapy
Chemotherapeutics
Drug delivery gemcitabine
Liposomes paclitaxel

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/FON.13.146

Cite this

@article{e82cf32582974a3a9110d7bd032dfccf,

title = "Liposomal chemotherapeutics",

abstract = "Currently, six liposomal chemotherapeutics have received clinical approval and many more are in clinical trials or undergoing preclinical evaluation. Liposomes exhibit low toxicity and improve the biopharmaceutical features and therapeutic index of drugs, thereby increasing efficacy and reducing side effects. In this review we discuss the advantages of using liposomes for the delivery of chemotherapeutics, Gemcitabine and paclitaxel have been chosen as examples to illustrate how the performance of a metabolically unstable or poorly water-soluble drug can be greatly improved by liposomal incorporation. We look at the beneficial effects of liposomes in a variety of solid and blood-borne tumors, including thyroid cancer, pancreatic cancer, breast cancer and multiple myeloma.",

keywords = "Cancer therapy, Chemotherapeutics, Drug delivery gemcitabine, Liposomes paclitaxel",

author = "Emanuela Gentile and Felisa Cilurzo and {Di Marzio}, Luisa and Maria Carafa and Ventura, {Cinzia Anna} and Joy Wolfram and Donatella Paolino and Christian Celia",

year = "2013",

doi = "10.2217/FON.13.146",

language = "English (US)",

volume = "9",

pages = "1849--1859",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "12",

}

TY - JOUR

T1 - Liposomal chemotherapeutics

AU - Gentile, Emanuela

AU - Cilurzo, Felisa

AU - Di Marzio, Luisa

AU - Carafa, Maria

AU - Ventura, Cinzia Anna

AU - Wolfram, Joy

AU - Paolino, Donatella

AU - Celia, Christian

PY - 2013

Y1 - 2013

N2 - Currently, six liposomal chemotherapeutics have received clinical approval and many more are in clinical trials or undergoing preclinical evaluation. Liposomes exhibit low toxicity and improve the biopharmaceutical features and therapeutic index of drugs, thereby increasing efficacy and reducing side effects. In this review we discuss the advantages of using liposomes for the delivery of chemotherapeutics, Gemcitabine and paclitaxel have been chosen as examples to illustrate how the performance of a metabolically unstable or poorly water-soluble drug can be greatly improved by liposomal incorporation. We look at the beneficial effects of liposomes in a variety of solid and blood-borne tumors, including thyroid cancer, pancreatic cancer, breast cancer and multiple myeloma.

AB - Currently, six liposomal chemotherapeutics have received clinical approval and many more are in clinical trials or undergoing preclinical evaluation. Liposomes exhibit low toxicity and improve the biopharmaceutical features and therapeutic index of drugs, thereby increasing efficacy and reducing side effects. In this review we discuss the advantages of using liposomes for the delivery of chemotherapeutics, Gemcitabine and paclitaxel have been chosen as examples to illustrate how the performance of a metabolically unstable or poorly water-soluble drug can be greatly improved by liposomal incorporation. We look at the beneficial effects of liposomes in a variety of solid and blood-borne tumors, including thyroid cancer, pancreatic cancer, breast cancer and multiple myeloma.

KW - Cancer therapy

KW - Chemotherapeutics

KW - Drug delivery gemcitabine

KW - Liposomes paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=84893828118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893828118&partnerID=8YFLogxK

U2 - 10.2217/FON.13.146

DO - 10.2217/FON.13.146

M3 - Article

C2 - 24295415

AN - SCOPUS:84893828118

SN - 1479-6694

VL - 9

SP - 1849

EP - 1859

JO - Future Oncology

JF - Future Oncology

IS - 12

ER -

Liposomal chemotherapeutics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this